BPA for rezdriffra
Active Awarded Last action
- Contract number
- 36E79725A0006
- Awardee
-
Madrigal Pharmaceuticals, Inc. UEI KA81N6BWY8L9
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 82% complete
- IDV ceiling
- $455,079.50
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement (BPA) was awarded on March 5, 2025, by the National Acquisition Center, a civilian federal agency, to Madrigal Pharmaceuticals, Inc. (UEI: KA81N6BWY8L9), a pharmaceutical company headquartered in Conshohocken, Pennsylvania. The contract carries a ceiling value of approximately $455,000 and is scheduled for ultimate completion on March 4, 2027. This single-award BPA was issued without set-aside provisions and falls under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule master contract. The primary product procured under this agreement is REZDIFFRA, an 80 milligram pharmaceutical treatment that represents Madrigal's core federal offering. The BPA structure enables the National Acquisition Center to issue individual delivery orders against this agreement, providing a streamlined procurement mechanism for federal healthcare agencies requiring consistent pharmaceutical supply.
Madrigal Pharmaceuticals' established track record with federal agencies, particularly the Department of Veterans Affairs through multiple Veterans Integrated Service Networks (VISN 5 and VISN 12), demonstrates the company's capability to deliver pharmaceutical products to federal healthcare procurement requirements. The BPA supports the government's objective of maintaining reliable access to REZDIFFRA across federal agencies while leveraging the efficiency of the indefinite delivery vehicle structure. By consolidating pharmaceutical procurement under a single-award agreement with predetermined pricing and terms, the National Acquisition Center reduces procurement cycle times and administrative burden while ensuring consistent product availability for federal healthcare operations through an established vendor with demonstrated performance on similar pharmaceutical supply contracts extending through October 2029.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0006?
36E79725A0006 was awarded to Madrigal Pharmaceuticals, Inc. by National Acquisition Center (Headquarters) on March 5, 2025.
How much is contract 36E79725A0006 worth?
36E79725A0006's own ceiling is $455,080.
Who can order from contract 36E79725A0006?
36E79725A0006 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0006 under another contract?
Yes. 36E79725A0006 is a blanket purchase agreement under 36F79725D0004, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0006 competed?
The extent of competition for 36E79725A0006 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV